How well are international guidelines followed for certain medications for high-risk pregnancies?
Medical Xpress
February 25, 2026
AI-Generated Deep Dive Summary
A recent review published in the *International Journal of Gynecology & Obstetrics* highlights significant variability in the use of prenatal magnesium sulfate and steroids across countries, despite their proven benefits for preterm infants. These medications are internationally recommended to reduce the risks of cerebral palsy and respiratory complications, yet adherence remains inconsistent both between and within nations. This discrepancy raises concerns about the implementation of evidence-based practices in maternal care.
The study points to several factors contributing to the lack of uniformity, including differences in healthcare systems, provider awareness, and logistical challenges. While guidelines from organizations like the World Health Organization (WHO) and Cochrane Collaboration strongly endorse these treatments for women at risk of preterm delivery, regional variations in medical practices continue to hinder their widespread adoption.
The implications of this variability are profound. Effective use of magnesium sulfate and steroids can significantly reduce complications in preterm infants, potentially lowering long-term healthcare costs and improving outcomes for families. Addressing the barriers to implementation is crucial to ensuring that all pregnant women at risk have access to these life-saving interventions. The findings underscore the need for targeted strategies to enhance awareness, improve healthcare infrastructure, and promote consistent adherence to evidence-based guidelines globally.
Verticals
healthmedical
Originally published on Medical Xpress on 2/25/2026